{rfName}
El

Indexed in

License and use

Citations

2

Altmetrics

Analysis of institutional authors

Vera Mendoza, Maria IsabelAuthor

Share

December 2, 2019
Publications
>
Article
Diamond

Eluxadoline en el tratamiento del síndrome de intestino irritable con predominio de diarrea: Punto de vista SEPD

Publicated to:REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 109 (11): 788-794-794 - 2017-01-01 109(11), DOI: 10.17235/reed.2017.5078/2017

Authors: Vera Mendoza, María Isabel; Júdez Gutiérrez, Francisco Javier

Affiliations

Hospital Universitario Puerta de Hierro Majadahonda - Author
Sociedad Española de Patología Digestiva - Author

Abstract

Functional gut disorders, including diarrhea-predominant irritable bowel syndrome, are highly prevalent conditions worldwide that significantly impact health economy and patient quality of life, yet lacking fully satisfactory therapeutic options. These circumstances fostered research on various molecules with more specific therapeutic targets, including opioid receptors. Eluxadoline (Allergan's Vibercy® in the USA, Truberzi® in Europe) is a locally-acting mixed mu- and kappa-opioid receptor agonist, and delta-opioid receptor antagonist, that was licensed in 2015 by the Food and Drug Administration (FDA) and in 2016 by the European Medicines Agency (EMA) for use in diarrhea-predominant irritable bowel syndrome. Eluxadoline provides, with advantage over the current standard of care, control of both stool consistency and abdominal pain, good tolerability in most cases, and improved quality of life, hence it deserves consideration when approaching a patient with this disorder. As with any recently approved therapy, adequate pharmacovigilance is to be expected, as well as studies to inform on different scenarios such as on-demand therapy, loss of response assessment, use as rescue therapy for other molecules, and cost-effectiveness, to further characterize and more accurately position eluxadoline within the therapeutic spectrum.

Keywords

BiodiversidadeCiências biológicas iiFarmaciaGastroenterologyGastroenterology & hepatologyGeneral medicineMedicina iMedicina iiMedicina iiiMedicine (miscellaneous)Odontología

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, and although the journal is classified in the quartile Q4 (Agencia WoS (JCR)), its regional focus and specialization in Gastroenterology & Hepatology, give it significant recognition in a specific niche of scientific knowledge at an international level.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-04:

  • WoS: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-04:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 31 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

    It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

    • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

    Leadership analysis of institutional authors

    There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (VERA MENDOZA, MARIA ISABEL) .